ストックスクリーナーアプリを入手
0.6443
1.63%
-0.0107
前日終値:
$0.655
開ける：
$0.6404
24時間の取引高:
219.65K
Relative Volume:
0.43
時価総額：
$34.40M
収益：
-
当期純損益:
$-151.16M
株価収益率:
-0.2169
EPS:
-2.97
ネットキャッシュフロー:
$-130.08M
1週間 パフォーマンス:
-4.80%
1か月 パフォーマンス:
+38.11%
6か月 パフォーマンス:
-41.43%
1年 パフォーマンス:
-75.69%
1日の値動き範囲:
$0.6245
$0.6692
1週間の範囲:
$0.601
$0.6927
52週間の値動き範囲:
$0.404
$2.73
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
名前
Alx Oncology Holdings Inc
セクター
電話
650-466-7125
住所
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
ALXO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
0.6443 | 35.08M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-06 | アップグレード | Jefferies | Hold → Buy |
| 2024-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2024-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-08 | アップグレード | Jefferies | Hold → Buy |
| 2021-12-22 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-04-06 | 開始されました | UBS | Buy |
| 2021-02-10 | 開始されました | H.C. Wainwright | Buy |
| 2020-08-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-08-11 | 開始されました | Credit Suisse | Outperform |
| 2020-08-11 | 開始されました | Jefferies | Buy |
| 2020-08-11 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Alx Oncology Holdings Inc (ALXO) 最新ニュース
Alx Oncology Faces Nasdaq Delisting Risk Amid Stock Price Slump - MSN
ALX Oncology Holdings Receives Hold Rating from LifeSci Capital - AInvest
Healthcare Stocks Move in After-Market Session - AInvest
ALX Oncology shares fall 1.51% after-hours following Q2 2025 earnings call and investor presentation. - AInvest
Peninsula biotech company sets two clinical trials to revive its cancer-fighting fortunes - The Business Journals
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Q2 2025 Earnings Call Transcript - Insider Monkey
ALX Oncology Q2 2025 Earnings Call Transcript - MarketBeat
ALX Oncology shares rise 6.34% premarket after positive Q2 2025 results and clinical trial updates. - AInvest
ALX Oncology Holdings Inc Reports Promising Trial Results and Pipeline Progress - AInvest
ALX Oncology Holdings Inc (ALXO) Q2 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance
ALX Oncology Holdings Inc. Moves Into Overbought Range Analysts CautiousWeekly Watchlist of High Movers Released - 선데이타임즈
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
ALX Oncology Advances Cancer Therapy Pipeline - TipRanks
ALX Oncology's Strategic Momentum in Immuno-Oncology: Evaluating the Investment Potential of Evorpacept's Pipeline Progress - AInvest
ALX Oncology Holdings Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:ALXO) - Seeking Alpha
Transcript : ALX Oncology Holdings Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
ALX Oncology : Investor Presentation (d1ea01) - MarketScreener
ALX Oncology Holdings Earnings Preview: Analyst Estimates and Past Performance - AInvest
Earnings call transcript: ALS Oncology Q2 2025 reports EPS miss By Investing.com - Investing.com Canada
ALX Oncology Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ALX Oncology Appoints Dr. Curran to Board - TipRanks
ALX Oncology Reports Second Quarter 2025 Financial Results and P - GuruFocus
Q2 2025 ALX Oncology Holdings Inc Earnings Call Transcript - GuruFocus
ALX Oncology Q2 2025 slides: biomarker strategy shows promise as cash runway extends - Investing.com Canada
ALX Oncology Reports Significant Advances in Evorpacept Trials and Updates Corporate Strategy - Quiver Quantitative
ALX Oncology Holdings Inc. Provides Clinical Trail Update - MarketScreener
Using RSI to spot recovery in ALX Oncology Holdings Inc.Weekly Growth Portfolio Performance Summary - Newser
Does ALX Oncology Holdings Inc. align with a passive investing strategyQuick Win Portfolio Stocks - thegnnews.com
ALX Oncology Holdings Inc. stock trend forecastSector Rotation Outlook With Historical Summary - Newser
Visual trend scoring systems applied to ALX Oncology Holdings Inc.Steady Return Plan Based on Data Analysis - Newser
Why ALX Oncology Holdings Inc. stock attracts strong analyst attentionTechnical Trend Forecast for Investors - Newser
Is ALX Oncology Holdings Inc. stock poised for growthFree Daily Growth Stock Pick Reports - Newser
Is ALX Oncology Holdings Inc. stock bottoming outBreakout Stock Opportunities with Low Drawdown - Newser
Will ALX Oncology Holdings Inc. see short term momentumPredictive AI Engine for Smart Investing - Newser
What indicators show strength in ALX Oncology Holdings Inc.Proven Trading System with Consistent Gains - Newser
How Interest Rate Changes Impact ALX Oncology Holdings Inc. Stock PerformancePortfolio Building Plan and Summary Guide - Newser
Can machine learning forecast ALX Oncology Holdings Inc. recoveryFree Investment Plan With Growth Optimization - Newser
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight - GlobeNewswire Inc.
Developing predictive dashboards with ALX Oncology Holdings Inc. dataSwing Gain Strategy with Entry Forecast - Newser
How ALX Oncology Holdings Inc. stock performs during market volatilityFree Target Return Focused Trade Insights - Newser
Why ALX Oncology Holdings Inc. is moving todayPrice Action Trading with Volume Confirmation - Newser
Chart overlay techniques for tracking ALX Oncology Holdings Inc.Watchlist Generator for Smart Money Signals - Newser
Tools to monitor ALX Oncology Holdings Inc. recovery probabilityHigh Accuracy Trade Setup Identification - Newser
ALX Oncology Holdings Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Earnings Preview: ALX Oncology to Report Financial Results Post-market on August 12 - 富途牛牛
How to read the order book for ALX Oncology Holdings Inc.Smart Stock Forecast Using AI Algorithms - Newser
Custom watchlist performance reports with ANNAWSmart Trade Forecast Based on Neural Logic - Newser
ALX Oncology: Assessing Q2 2025 Earnings and Pipeline Catalysts for Immuno-Oncology Growth - AInvest
ALX Oncology Holdings Inc. to Report Second Quarter 2025 Financial Results and Business Update on August 12, 2025 - Quiver Quantitative
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 - GlobeNewswire
ALX Oncology Sets Date for Q2 2025 Earnings: Key Business Updates Expected from Cancer Drug Pipeline - Stock Titan
Alx Oncology Holdings Inc (ALXO) 財務データ
収益
当期純利益
現金流量
EPS
Alx Oncology Holdings Inc (ALXO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Pinto Shelly | SVP, FINANCE AND CAO |
Jun 30 '25 |
Sale |
0.43 |
1,532 |
659 |
88,820 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 19 '25 |
Sale |
1.15 |
550 |
633 |
87,352 |
| Pons Jaume | PRESIDENT & CSO |
Feb 19 '25 |
Sale |
1.15 |
1,326 |
1,525 |
579,388 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
1.15 |
2,159 |
2,483 |
170,270 |
| Pinto Shelly | Interim CFO |
Jan 06 '25 |
Sale |
1.80 |
2,221 |
3,998 |
87,902 |
| Pinto Shelly | Interim CFO |
Dec 30 '24 |
Sale |
1.58 |
1,426 |
2,253 |
90,123 |
| Pons Jaume | PRESIDENT & CSO |
Dec 30 '24 |
Sale |
1.58 |
10,796 |
17,060 |
580,714 |
| Hemrajani Rekha | Director |
Dec 02 '24 |
Buy |
1.55 |
30,000 |
46,404 |
33,000 |
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):